| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Ability of synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa to afford protection against P. aeruginosa infection in a murine acute pneumonia model
|
Hughes, Eileen E.
|
|
1995
|
13 |
18 |
p. 1750-1753
4 p.
|
artikel
|
| 2 |
An immunogenic polypeptide is used in a subunit vaccine against malaria; Plasmodium falciparum or Plasmodium vivax recombinant apical membrane antigen-1 expression in Escherichia coli
|
|
|
1995
|
13 |
18 |
p. 1815-
1 p.
|
artikel
|
| 3 |
Calendar
|
|
|
1995
|
13 |
18 |
p. 1816-
1 p.
|
artikel
|
| 4 |
Caseous lymphadenitis vaccine development: site-specific inactivation of the Corynebacterium pseudotuberculosis phospholipase D gene
|
Tachedjian, Mary
|
|
1995
|
13 |
18 |
p. 1785-1792
8 p.
|
artikel
|
| 5 |
Effect of vaccination with a recombinant Bm86 antigen preparation on natural infestations of Boophilus microplus in grazing dairy and beef pure and cross-bred cattle in Brazil
|
Rodríguez, Manuel
|
|
1995
|
13 |
18 |
p. 1804-1808
5 p.
|
artikel
|
| 6 |
Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs
|
Ivins, Bruce
|
|
1995
|
13 |
18 |
p. 1779-1784
6 p.
|
artikel
|
| 7 |
Experimental quantification of transmission of genetically engineered pseudorabies virus
|
Mulder, W.A.M.
|
|
1995
|
13 |
18 |
p. 1763-1769
7 p.
|
artikel
|
| 8 |
Immunity to rubella before and after vaccination against measles, mumps and rubella (MMR) at 12 years of age of the first generation offered MMR vaccination in Sweden at 18 months
|
Böttiger, Margareta
|
|
1995
|
13 |
18 |
p. 1759-1762
4 p.
|
artikel
|
| 9 |
Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells
|
Moore, Anne
|
|
1995
|
13 |
18 |
p. 1741-1749
9 p.
|
artikel
|
| 10 |
Interferon-γ inductive effect of liposomes as an immunoadjuvant
|
Aramaki, Yukihiko
|
|
1995
|
13 |
18 |
p. 1809-1814
6 p.
|
artikel
|
| 11 |
Melanoma associated antigen, gp100; recombinant melanoma tumor-associated antigen preparation for use in a recombinant vaccine and genetic immunization
|
|
|
1995
|
13 |
18 |
p. 1815-
1 p.
|
artikel
|
| 12 |
Melanoma-specific immunogen comprising epitopes homologous with pMel17; HLA-A2-restricted epitope, melanoma tumor-associated antigen pMel-17 and/or tyrosinase gene cloning and expression using a vector for antitumor recombinant vaccine construction
|
|
|
1995
|
13 |
18 |
p. 1815-
1 p.
|
artikel
|
| 13 |
New mosaic hepatitis E virus polypeptides; recombinant protein production by vector expression for use as a recombinant vaccine
|
|
|
1995
|
13 |
18 |
p. 1815-
1 p.
|
artikel
|
| 14 |
Optimization of the intestinal lavage procedure for determination of intestinal immune responses
|
Åhrén, Christina
|
|
1995
|
13 |
18 |
p. 1754-1758
5 p.
|
artikel
|
| 15 |
Overview: practical insights from comparative immunology and pathogenesis of AIDS, hepatitis B, and measles for developing an HIV vaccine
|
Hilleman, Maurice R.
|
|
1995
|
13 |
18 |
p. 1733-1740
8 p.
|
artikel
|
| 16 |
Preparation and characterization of a purified influenza virus neuraminidase vaccine
|
Hocart, Michael
|
|
1995
|
13 |
18 |
p. 1793-1798
6 p.
|
artikel
|
| 17 |
Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans
|
Kilbourne, Edwin D.
|
|
1995
|
13 |
18 |
p. 1799-1803
5 p.
|
artikel
|
| 18 |
Recombinant antibodies containing an engineered B-cell epitope capable of eliciting conformation-specific antibody responses
|
Cook, Jeremy
|
|
1995
|
13 |
18 |
p. 1770-1778
9 p.
|
artikel
|
| 19 |
Use of prolactin or prolactic cDNA; for genetic immunization against infectious disease and viral disease
|
|
|
1995
|
13 |
18 |
p. 1815-
1 p.
|
artikel
|
Tijdschrift beschrijving